
Annual report 2023
added 12-13-2025
Silence Therapeutics plc EBITDA 2011-2025 | SLN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Silence Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -45.8 M | -35.8 M | -22.7 M | -20.6 M | -14 M | -11.6 M | -9.59 M | -11.8 M | -8.7 M | -5.31 M | -5.02 M |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.02 M | -45.8 M | -17.4 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
-76.7 M | $ 4.79 | 2.35 % | $ 795 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Aclaris Therapeutics
ACRS
|
-141 M | $ 3.04 | 4.83 % | $ 235 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
BioVie
BIVI
|
-17.8 M | $ 1.27 | -3.05 % | $ 1.88 M | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 1.17 | 4.46 % | $ 6.38 M | ||
|
Aptevo Therapeutics
APVO
|
-24.2 M | $ 0.93 | -8.81 % | $ 257 K | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
-396 M | - | 0.49 % | $ 251 B | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
-216 M | - | - | $ 546 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 212.81 | 1.71 % | $ 5 B | ||
|
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 0.18 | -25.03 % | $ 392 M | ||
|
Catalyst Biosciences
CBIO
|
-66.2 M | $ 12.37 | 2.06 % | $ 814 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
-442 M | - | - | $ 7.29 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.1 | 0.16 % | $ 7.46 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Celsion Corporation
CLSN
|
-18.9 M | - | -6.63 % | $ 13.9 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 95.03 | 0.95 % | $ 27.2 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
138 M | $ 83.59 | 1.95 % | $ 8.63 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
196 M | $ 24.45 | 0.91 % | $ 2.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
234 M | $ 26.81 | 1.36 % | $ 1.3 B | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 9.48 | 0.96 % | $ 139 M | ||
|
Cortexyme
CRTX
|
-34.3 M | - | -1.05 % | $ 67.1 M | ||
|
CTI BioPharma Corp.
CTIC
|
-77.8 M | - | - | $ 1.2 B | ||
|
Arena Pharmaceuticals
ARNA
|
-620 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 591.15 | 0.02 % | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.53 | -0.39 % | $ 15.9 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | $ 92.45 | 0.34 % | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
-192 M | $ 26.83 | 0.94 % | $ 1.73 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K |